Key Events This Week
1 June: Golden Cross formation signalling potential bullish breakout
2 June: Upgrade to Buy rating by MarketsMOJO on strong financials and technicals
2 June: Strong technical momentum confirmed amid bullish shift
3 June: Technical momentum shifts to mildly bullish with price consolidation
5 June: Week closes at Rs.16,812.90 (-1.49%)

Neuland Laboratories Ltd is Rated Buy
2026-06-13 10:10:05Neuland Laboratories Ltd is rated Buy by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 June 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
Neuland Laboratories Ltd Technical Momentum Shifts Signal Bullish Outlook
2026-06-10 08:00:56Neuland Laboratories Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by a combination of technical indicators including MACD, RSI, Bollinger Bands, and moving averages, suggesting a strengthening price momentum amid a positive market backdrop for the pharmaceuticals and biotechnology sector.
Read full news article
Neuland Laboratories Ltd: Technical Momentum Shifts Signal Mildly Bullish Outlook
2026-06-03 08:00:42Neuland Laboratories Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a transition from bullish to mildly bullish trends. Despite a slight dip in the daily price, the stock’s medium- and long-term indicators reveal a complex interplay of bullish and bearish signals, prompting a reassessment of its near-term outlook.
Read full news article
Neuland Laboratories Upgraded to Buy on Strong Financials and Bullish Technicals
2026-06-02 08:17:27Neuland Laboratories Ltd has seen its investment rating upgraded from Hold to Buy, reflecting significant improvements across quality, valuation, financial trends, and technical indicators. This upgrade, effective from 1 June 2026, comes amid robust quarterly results, sustained long-term growth, and a shift to bullish technical momentum, positioning the small-cap pharmaceutical firm favourably against market benchmarks.
Read full news article
Neuland Laboratories Ltd Shows Strong Technical Momentum Amid Bullish Shift
2026-06-02 08:01:32Neuland Laboratories Ltd has exhibited a notable shift in technical momentum, transitioning from a sideways trend to a bullish stance. Supported by a strong MarketsMOJO Mojo Score upgrade to 77.0 and a Buy grade, the small-cap pharmaceutical player is demonstrating robust price action and technical signals that suggest sustained upward potential.
Read full news article
Golden Cross Confirmed: Do Neuland Laboratories Ltd's Other Technical Indicators Agree?
2026-06-01 18:00:19The 50-day moving average has crossed above the 200-day moving average for Neuland Laboratories Ltd, signalling a golden cross on 1 Jun 2026. While this technical event often suggests a shift towards bullish momentum, the broader technical and fundamental context presents a nuanced picture that merits closer examination.
Read full news articleNeuland Laboratories Gains 2.61%: Technical Shift and Valuation Concerns Shape the Week
2026-05-31 13:00:05
Key Events This Week
May 25: Stock opens at Rs.16,742.45, Sensex gains 1.23%
May 26: Stock surges 1.88% to Rs.17,056.90 despite Sensex decline
May 27: Downgrade to Hold announced amid mixed technical and valuation signals
May 29: Stock closes strong at Rs.17,067.90, up 1.84% on the day
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
05-Jun-2026 | Source : BSEIntimation about Schedule of Analyst / Institutional Investor Meeting on June 11 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
03-Jun-2026 | Source : BSEIntimation about Schedule of Analyst / Institutional Investor Meeting on June 8 & 9 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
31-May-2026 | Source : BSEIntimation about Schedule of Analyst / Institutional Investor Meeting on June 5 2026
Corporate Actions
No Upcoming Board Meetings
Neuland Laboratories Ltd has declared 340% dividend, ex-date: 24 Jul 26
No Splits history available
No Bonus history available
Neuland Laboratories Ltd has announced 4:25 rights issue, ex-date: 13 Aug 14







